Kim Eun-Yeong, Choi Hee-Jung, Chung Tae-Wook, Jang Se Bok, Kim Kibong, Ha Ki-Tae
Department of Korean Medical Science, School of Korean Medicine and Korean Medicine Research Center for Healthy Aging, Pusan National University, Yangsan 626-870, Republic of Korea.
Department of Molecular Biology, College of Natural Sciences, Pusan National University, Busan 609-735, Republic of Korea.
J Microbiol Biotechnol. 2015 Aug;25(8):1307-14. doi: 10.4014/jmb.1501.01094.
Leukemia inhibitory factor (LIF) is a member of the IL-6 cytokine family, having pleiotropic actions such as maintaining stem cell pluripotency and enabling blastocyst implantation. Because the action of LIF is mediated by a ligand-receptor interaction with the LIF receptor (LIF-R), an antagonist for LIF-R has been developed to inhibit LIF-induced signaling. In this study, we present a novel method for the production and purification of an antagonist to human LIF-R (hLA). His-tagged hLA was expressed in E. coli, and simple purification methods without any endopeptidase cleavage were designed. In addition, we determined the optimal temperature conditions for enhancing the production of soluble hLA. Finally, the bioactivity of His-tagged hLA was examined using STAT3 phosphorylation and receptivity of human endometrial ECC-1 cells. Our strategy provides a rapid and efficient method to produce biologically active recombinant hLA.
白血病抑制因子(LIF)是白细胞介素-6细胞因子家族的成员,具有多效性作用,如维持干细胞多能性和使囊胚着床。由于LIF的作用是通过与LIF受体(LIF-R)的配体-受体相互作用介导的,因此已开发出一种LIF-R拮抗剂来抑制LIF诱导的信号传导。在本研究中,我们提出了一种生产和纯化人LIF-R拮抗剂(hLA)的新方法。His标签化的hLA在大肠杆菌中表达,并设计了无需任何内肽酶切割的简单纯化方法。此外,我们确定了提高可溶性hLA产量的最佳温度条件。最后,使用STAT3磷酸化和人子宫内膜ECC-1细胞的接受性检测了His标签化hLA的生物活性。我们的策略提供了一种快速有效的方法来生产具有生物活性的重组hLA。